Add to ORKGThe theme of this review is to summarize the evolving processes in cardiovascular drug discovery and development within a large pharmaceutical company. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the effectiveness of research collaboration between the two constitu-encies, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized. The need for improved therapy in many cardiovascular indications remains high, but the feasibility in making progress, despite the advances in molecular biology and genomics, is also assessed. In a recent article on our understanding of theevolution of coronary a...
Cardiovascular research has underpinned major advances in patient care but the introduction of new t...
Cardiovascular disease (CVD) is the leading cause of death in the United States accounting for appro...
AbstractDespite the global burden of cardiovascular disease, investment in cardiovascular drug devel...
Aims Cardiovascular disease is the most common cause of mortality and morbidity in the world, but th...
Aims Cardiovascular disease is the most common cause of mortality and morbidity in the world, but th...
SummaryCardiovascular disease remains a leading cause of death, but stakeholders have recently raise...
This study examines the invention, innovation, introduction and use of a new drug therapy for corona...
ABSTRACT Innovation is one of the pharmaceutical industry’s most defining characteristics. New medi...
Background: Cardiovascular disease is the leading cause of morbidity and mortality worldwide in deve...
Pharmaceutical and medicinal R&D projects have evolved during recent decades into extremely intricat...
1. Introduction discussed herein because of space limitations (and our own short-sightedness). Sever...
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.Includes bibliographical...
While we continue to wrestle with the immense challenge of implementing equitable access to establis...
International audienceAbstract Whilst we continue to wrestle with the immense challenge of implement...
Cardiovascular research has underpinned major advances in patient care but the introduction of new t...
Cardiovascular disease (CVD) is the leading cause of death in the United States accounting for appro...
AbstractDespite the global burden of cardiovascular disease, investment in cardiovascular drug devel...
Aims Cardiovascular disease is the most common cause of mortality and morbidity in the world, but th...
Aims Cardiovascular disease is the most common cause of mortality and morbidity in the world, but th...
SummaryCardiovascular disease remains a leading cause of death, but stakeholders have recently raise...
This study examines the invention, innovation, introduction and use of a new drug therapy for corona...
ABSTRACT Innovation is one of the pharmaceutical industry’s most defining characteristics. New medi...
Background: Cardiovascular disease is the leading cause of morbidity and mortality worldwide in deve...
Pharmaceutical and medicinal R&D projects have evolved during recent decades into extremely intricat...
1. Introduction discussed herein because of space limitations (and our own short-sightedness). Sever...
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2006.Includes bibliographical...
While we continue to wrestle with the immense challenge of implementing equitable access to establis...
International audienceAbstract Whilst we continue to wrestle with the immense challenge of implement...
Cardiovascular research has underpinned major advances in patient care but the introduction of new t...
Cardiovascular disease (CVD) is the leading cause of death in the United States accounting for appro...
AbstractDespite the global burden of cardiovascular disease, investment in cardiovascular drug devel...